Plasmacytoid Dendritic Cells as a Novel Cell-Based Cancer Immunotherapy
Abstract
:1. Introduction
2. pDC Biology: Phenotype and Function
3. pDCs in Cancer
3.1. Impairment of pDCs in the TME
3.2. pDCs in Antitumor Immunity
4. pDC-Based Cancer Immunotherapy
4.1. Immunotherapy Strategies Based on Activation of TLR Signalling
4.2. DC Mobilization for Cancer Immunotherapy
4.3. pDC-Based Vaccines for Cancer Immunotherapy
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
APC | Antigen-presenting cell |
BM | Bone marrow |
BMT | Bone marrow transplantation |
BST2 | Bone marrow stromal antigen 2 |
CBT | Cord blood transplantation |
cDCs | Conventional DCs |
CLR | C-type lectin-like receptors |
CRPC | Castration-resistant prostate cancer |
CTLs | CD8+ cytotoxic T lymphocytes |
CXCL | C-X-C motif chemokine ligands |
CXCR3 | C-X-C motif chemokine receptor 3 |
DCs | Dendritic cells |
Flt3L | Fms-like tyrosine kinase 3-ligand |
GM-CSF | Granulocyte-macrophage colony stimulating factor |
HNSCC | Head and neck squamous cell carcinomas |
HSPCs | Hematopoietic stem and progenitor cells |
IDO | Immunoregulatory enzyme indoleamine 2,3-dioxygenase |
IFN-I | Type I Interferon |
IFNR | IFN receptor |
IL-3 | Interleukin 3 |
ILT7 | Immunoglobulin-like cell transcript 7 |
IMQ | Imiquimod |
IRF | Interferon Regulatory Factor |
MHC | Major histocompatibility complex |
moDCs | Monocyte-derived dendritic cells |
NK | Natural killer |
OS | Overall survival |
PBMCs | Peripheral blood mononuclear cells |
pDCs | Plasmacytoid DCs |
PFS | Progression-free survival |
PGE2 | Prostaglandin E2 |
SLN | Sentinel lymph node |
TAA | Tumor-associated antigens |
TGF-β | Transforming growth factor- β |
TILs | Tumor-infiltrating lymphocytes |
TLR | Toll-like receptors |
TME | Tumor microenvironment |
TNF | Tumor necrosis factor |
TRAIL-R2 | TRAIL receptor-2 |
Treg | Regulatory T cells |
References
- Chen, D.S.; Mellman, I. Oncology meets immunology: The cancer-immunity cycle. Immunity 2013, 39, 1–10. [Google Scholar] [CrossRef]
- Wculek, S.K.; Cueto, F.J.; Mujal, A.M.; Melero, I.; Krummel, M.F.; Sancho, D. Dendritic cells in cancer immunology and immunotherapy. Nat. Rev. Immunol. 2020, 20, 7–24. [Google Scholar] [CrossRef]
- Van der Sluis, R.M.; Egedal, J.H.; Jakobsen, M.R. Plasmacytoid Dendritic Cells as Cell-Based Therapeutics: A Novel Immunotherapy to Treat Human Immunodeficiency Virus Infection? Front. Cell Infect. Microbiol. 2020, 10, 249. [Google Scholar] [CrossRef] [PubMed]
- Collin, M.; Bigley, V. Human dendritic cell subsets: An update. Immunology 2018, 154, 3–20. [Google Scholar] [CrossRef] [PubMed]
- Villani, A.C.; Satija, R.; Reynolds, G.; Sarkizova, S.; Shekhar, K.; Fletcher, J.; Griesbeck, M.; Butler, A.; Zheng, S.; Lazo, S.; et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science 2017, 356, eaah4573. [Google Scholar] [CrossRef]
- Ginhoux, F.; Guilliams, M.; Merad, M. Expanding dendritic cell nomenclature in the single-cell era. Nat. Rev. Immunol. 2022, 22, 67–68. [Google Scholar] [CrossRef]
- Lennert, K.; Remmele, W. Karyometrische Untersuchungen an Lymphknotenzellen des Menschen. Acta Haematol. 1958, 19, 99–113. [Google Scholar] [CrossRef]
- Cella, M.; Jarrossay, D.; Facchetti, F.; Alebardi, O.; Nakajima, H.; Lanzavecchia, A.; Colonna, M. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat. Med. 1999, 5, 919–923. [Google Scholar] [CrossRef]
- Siegal, F.P.; Kadowaki, N.; Shodell, M.; Fitzgerald-Bocarsly, P.A.; Shah, K.; Ho, S.; Antonenko, S.; Liu, Y.J. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999, 284, 1835–1837. [Google Scholar] [CrossRef]
- Yang, G.X.; Lian, Z.X.; Kikuchi, K.; Moritoki, Y.; Ansari, A.A.; Liu, Y.J.; Ikehara, S.; Gershwin, M.E. Plasmacytoid dendritic cells of different origins have distinct characteristics and function: Studies of lymphoid progenitors versus myeloid progenitors. J. Immunol. 2005, 175, 7281–7287. [Google Scholar] [CrossRef] [Green Version]
- Rodrigues, P.F.; Alberti-Servera, L.; Eremin, A.; Grajales-Reyes, G.E.; Ivanek, R.; Tussiwand, R. Distinct progenitor lineages contribute to the heterogeneity of plasmacytoid dendritic cells. Nat. Immunol. 2018, 19, 711–722. [Google Scholar] [CrossRef]
- Dress, R.J.; Dutertre, C.A.; Giladi, A.; Schlitzer, A.; Low, I.; Shadan, N.B.; Tay, A.; Lum, J.; Kairi, M.; Hwang, Y.Y.; et al. Plasmacytoid dendritic cells develop from Ly6D(+) lymphoid progenitors distinct from the myeloid lineage. Nat. Immunol. 2019, 20, 852–864. [Google Scholar] [CrossRef] [PubMed]
- Proietto, A.I.; Mittag, D.; Roberts, A.W.; Sprigg, N.; Wu, L. The equivalents of human blood and spleen dendritic cell subtypes can be generated in vitro from human CD34+ stem cells in the presence of fms-like tyrosine kinase 3 ligand and thrombopoietin. Cell. Mol. Immunol. 2012, 9, 446–454. [Google Scholar] [CrossRef] [PubMed]
- Grouard, G.; Rissoan, M.-C.; Filgueira, L.; Durand, I.; Banchereau, J.; Liu, Y.-J. The Enigmatic Plasmacytoid T Cells Develop into Dendritic Cells with Interleukin (IL)-3 and CD40-Ligand. J. Exp. Med. 1997, 185, 1101–1112. [Google Scholar] [CrossRef] [PubMed]
- Demoulin, S.; Roncarati, P.; Delvenne, P.; Hubert, P. Production of large numbers of plasmacytoid dendritic cells with functional activities from CD34(+) hematopoietic progenitor cells: Use of interleukin-3. Exp. Hematol. 2012, 40, 268–278. [Google Scholar] [CrossRef]
- Kawai, T.; Sato, S.; Ishii, K.J.; Coban, C.; Hemmi, H.; Yamamoto, M.; Terai, K.; Matsuda, M.; Inoue, J.; Uematsu, S.; et al. Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat. Immunol. 2004, 5, 1061–1068. [Google Scholar] [CrossRef]
- Wimmers, F.; Subedi, N.; van Buuringen, N.; Heister, D.; Vivie, J.; Beeren-Reinieren, I.; Woestenenk, R.; Dolstra, H.; Piruska, A.; Jacobs, J.F.M.; et al. Single-cell analysis reveals that stochasticity and paracrine signaling control interferon-alpha production by plasmacytoid dendritic cells. Nat. Commun. 2018, 9, 3317. [Google Scholar] [CrossRef]
- Gibson, S.J.; Lindh, J.M.; Riter, T.R.; Gleason, R.M.; Rogers, L.M.; Fuller, A.E.; Oesterich, J.L.; Gorden, K.B.; Qiu, X.; McKane, S.W.; et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell. Immunol. 2002, 218, 74–86. [Google Scholar] [CrossRef]
- Swiecki, M.; Colonna, M. The multifaceted biology of plasmacytoid dendritic cells. Nat. Rev. Immunol. 2015, 15, 471–485. [Google Scholar] [CrossRef]
- van Beek, J.J.P.; Florez-Grau, G.; Gorris, M.A.J.; Mathan, T.S.M.; Schreibelt, G.; Bol, K.F.; Textor, J.; de Vries, I.J.M. Human pDCs Are Superior to cDC2s in Attracting Cytolytic Lymphocytes in Melanoma Patients Receiving DC Vaccination. Cell Rep. 2020, 30, 1027–1038.e1024. [Google Scholar] [CrossRef] [Green Version]
- Yun, T.J.; Igarashi, S.; Zhao, H.; Perez, O.A.; Pereira, M.R.; Zorn, E.; Shen, Y.; Goodrum, F.; Rahman, A.; Sims, P.A.; et al. Human plasmacytoid dendritic cells mount a distinct antiviral response to virus-infected cells. Sci. Immunol. 2021, 6, eabc7302. [Google Scholar] [CrossRef] [PubMed]
- Dzionek, A.; Fuchs, A.; Schmidt, P.; Cremer, S.; Zysk, M.; Miltenyi, S.; Buck, D.W.; Schmitz, J. BDCA-2, BDCA-3, and BDCA-4: Three markers for distinct subsets of dendritic cells in human peripheral blood. J. Immunol. 2000, 165, 6037–6046. [Google Scholar] [CrossRef] [PubMed]
- Matsui, T.; Connolly, J.E.; Michnevitz, M.; Chaussabel, D.; Yu, C.I.; Glaser, C.; Tindle, S.; Pypaert, M.; Freitas, H.; Piqueras, B.; et al. CD2 distinguishes two subsets of human plasmacytoid dendritic cells with distinct phenotype and functions. J. Immunol. 2009, 182, 6815–6823. [Google Scholar] [CrossRef] [PubMed]
- Bryant, C.; Fromm, P.D.; Kupresanin, F.; Clark, G.; Lee, K.; Clarke, C.; Silveira, P.A.; Suen, H.; Brown, R.; Newman, E.; et al. A CD2 high-expressing stress-resistant human plasmacytoid dendritic-cell subset. Immunol. Cell Biol. 2016, 94, 447–457. [Google Scholar] [CrossRef] [PubMed]
- Alculumbre, S.G.; Saint-Andre, V.; Di Domizio, J.; Vargas, P.; Sirven, P.; Bost, P.; Maurin, M.; Maiuri, P.; Wery, M.; Roman, M.S.; et al. Diversification of human plasmacytoid predendritic cells in response to a single stimulus. Nat. Immunol. 2018, 19, 63–75. [Google Scholar] [CrossRef]
- Ghanem, M.H.; Shih, A.J.; Khalili, H.; Werth, E.G.; Chakrabarty, J.K.; Brown, L.M.; Simpfendorfer, K.R.; Gregersen, P.K. Proteomic and Single-Cell Transcriptomic Dissection of Human Plasmacytoid Dendritic Cell Response to Influenza Virus. Front. Immunol. 2022, 13, 814627. [Google Scholar] [CrossRef]
- Reizis, B. Plasmacytoid Dendritic Cells: Development, Regulation, and Function. Immunity 2019, 50, 37–50. [Google Scholar] [CrossRef]
- Zhou, F. Molecular Mechanisms of IFN-γ to Up-Regulate MHC Class I Antigen Processing and Presentation. Int. Rev. Immunol. 2009, 28, 239–260. [Google Scholar] [CrossRef]
- Tel, J.; Aarntzen, E.H.; Baba, T.; Schreibelt, G.; Schulte, B.M.; Benitez-Ribas, D.; Boerman, O.C.; Croockewit, S.; Oyen, W.J.; van Rossum, M.; et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res. 2013, 73, 1063–1075. [Google Scholar] [CrossRef]
- Westdorp, H.; Creemers, J.H.A.; van Oort, I.M.; Schreibelt, G.; Gorris, M.A.J.; Mehra, N.; Simons, M.; de Goede, A.L.; van Rossum, M.M.; Croockewit, A.J.; et al. Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer. J. Immunother. Cancer 2019, 7, 302. [Google Scholar] [CrossRef]
- Charles, J.; Chaperot, L.; Hannani, D.; Bruder Costa, J.; Templier, I.; Trabelsi, S.; Gil, H.; Moisan, A.; Persoons, V.; Hegelhofer, H.; et al. An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial. Oncoimmunology 2020, 9, 1738812. [Google Scholar] [CrossRef] [PubMed]
- Hartmann, E.; Wollenberg, B.; Rothenfusser, S.; Wagner, M.; Wellisch, D.; Mack, B.; Giese, T.; Gires, O.; Endres, S.; Hartmann, G. Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res. 2003, 63, 6478–6487. [Google Scholar] [PubMed]
- Poropatich, K.; Dominguez, D.; Chan, W.C.; Andrade, J.; Zha, Y.; Wray, B.; Miska, J.; Qin, L.; Cole, L.; Coates, S.; et al. OX40+ plasmacytoid dendritic cells in the tumor microenvironment promote antitumor immunity. J. Clin. Invest. 2020, 130, 3528–3542. [Google Scholar] [CrossRef] [PubMed]
- Treilleux, I.; Blay, J.-Y.; Bendriss-Vermare, N.; Ray-Coquard, I.; Bachelot, T.; Guastalla, J.-P.; Bremond, A.; Goddard, S.; Pin, J.-J.; Barthelemy-Dubois, C.; et al. Dendritic Cell Infiltration and Prognosis of Early Stage Breast Cancer. Clin. Cancer Res. 2004, 10, 7466–7474. [Google Scholar] [CrossRef]
- Sisirak, V.; Faget, J.; Gobert, M.; Goutagny, N.; Vey, N.; Treilleux, I.; Renaudineau, S.; Poyet, G.; Labidi-Galy, S.I.; Goddard-Leon, S.; et al. Impaired IFN-α Production by Plasmacytoid Dendritic Cells Favors Regulatory T-cell Expansion That May Contribute to Breast Cancer Progression. Cancer Res. 2012, 72, 5188–5197. [Google Scholar] [CrossRef]
- Oshi, M.; Newman, S.; Tokumaru, Y.; Yan, L.; Matsuyama, R.; Kalinski, P.; Endo, I.; Takabe, K. Plasmacytoid Dendritic Cell (pDC) Infiltration Correlate with Tumor Infiltrating Lymphocytes, Cancer Immunity, and Better Survival in Triple Negative Breast Cancer (TNBC) More Strongly than Conventional Dendritic Cell (cDC). Cancers 2020, 12, 3342. [Google Scholar] [CrossRef]
- Tian, S.; Yan, L.; Fu, L.; Zhang, Z.; Zhang, J.; Meng, G.; Zhang, W. A Comprehensive Investigation to Reveal the Relationship Between Plasmacytoid Dendritic Cells and Breast Cancer by Multiomics Data Analysis. Front. Cell Dev. Biol. 2021, 9, 640476. [Google Scholar] [CrossRef]
- Charles, J.; Di Domizio, J.; Salameire, D.; Bendriss-Vermare, N.; Aspord, C.; Muhammad, R.; Lefebvre, C.; Plumas, J.; Leccia, M.T.; Chaperot, L. Characterization of circulating dendritic cells in melanoma: Role of CCR6 in plasmacytoid dendritic cell recruitment to the tumor. J. Invest. Dermatol. 2010, 130, 1646–1656. [Google Scholar] [CrossRef]
- Vescovi, R.; Monti, M.; Moratto, D.; Paolini, L.; Consoli, F.; Benerini, L.; Melocchi, L.; Calza, S.; Chiudinelli, M.; Rossi, G.; et al. Collapse of the Plasmacytoid Dendritic Cell Compartment in Advanced Cutaneous Melanomas by Components of the Tumor Cell Secretome. Cancer Immunol. Res. 2019, 7, 12–28. [Google Scholar] [CrossRef]
- Plesca, I.; Benešová, I.; Beer, C.; Sommer, U.; Müller, L.; Wehner, R.; Heiduk, M.; Aust, D.; Baretton, G.; Bachmann, M.P.; et al. Clinical Significance of Tumor-Infiltrating Conventional and Plasmacytoid Dendritic Cells in Pancreatic Ductal Adenocarcinoma. Cancers 2022, 14, 1216. [Google Scholar] [CrossRef]
- Kießler, M.; Plesca, I.; Sommer, U.; Wehner, R.; Wilczkowski, F.; Müller, L.; Tunger, A.; Lai, X.; Rentsch, A.; Peuker, K.; et al. Tumor-infiltrating plasmacytoid dendritic cells are associated with survival in human colon cancer. J. Immuno. Ther. Cancer 2021, 9, e001813. [Google Scholar] [CrossRef] [PubMed]
- Shi, W.; Li, X.; Porter, J.L.; Ostrodi, D.H.; Yang, B.; Li, J.; Wang, Y.; Zhang, J.; Bai, L.; Jiao, S. Level of plasmacytoid dendritic cells is increased in non-small cell lung carcinoma. Tumour. Biol. 2014, 35, 2247–2252. [Google Scholar] [CrossRef] [PubMed]
- Hoffmann, C.; Noel, F.; Grandclaudon, M.; Massenet-Regad, L.; Michea, P.; Sirven, P.; Faucheux, L.; Surun, A.; Lantz, O.; Bohec, M.; et al. PD-L1 and ICOSL discriminate human Secretory and Helper dendritic cells in cancer, allergy and autoimmunity. Nat. Commun. 2022, 13, 1983. [Google Scholar] [CrossRef] [PubMed]
- Pang, L.; Ng, K.T.; Liu, J.; Yeung, W.O.; Zhu, J.; Chiu, T.S.; Liu, H.; Chen, Z.; Lo, C.M.; Man, K. Plasmacytoid dendritic cells recruited by HIF-1alpha/eADO/ADORA1 signaling induce immunosuppression in hepatocellular carcinoma. Cancer Lett. 2021, 522, 80–92. [Google Scholar] [CrossRef]
- Bekeredjian-Ding, I.; Schafer, M.; Hartmann, E.; Pries, R.; Parcina, M.; Schneider, P.; Giese, T.; Endres, S.; Wollenberg, B.; Hartmann, G. Tumour-derived prostaglandin E and transforming growth factor-beta synergize to inhibit plasmacytoid dendritic cell-derived interferon-alpha. Immunology 2009, 128, 439–450. [Google Scholar] [CrossRef]
- Zhu, S.; Yang, N.; Wu, J.; Wang, X.; Wang, W.; Liu, Y.J.; Chen, J. Tumor microenvironment-related dendritic cell deficiency: A target to enhance tumor immunotherapy. Pharmacol. Res. 2020, 159, 104980. [Google Scholar] [CrossRef]
- Tiwari, R.; de la Torre, J.C.; McGavern, D.B.; Nayak, D. Beyond Tethering the Viral Particles: Immunomodulatory Functions of Tetherin (BST-2). DNA Cell Biol. 2019, 38, 1170–1177. [Google Scholar] [CrossRef]
- Cao, W.; Bover, L.; Cho, M.; Wen, X.; Hanabuchi, S.; Bao, M.; Rosen, D.B.; Wang, Y.H.; Shaw, J.L.; Du, Q.; et al. Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction. J. Exp. Med. 2009, 206, 1603–1614. [Google Scholar] [CrossRef]
- Tsukamoto, N.; Okada, S.; Onami, Y.; Sasaki, Y.; Umezawa, K.; Kawakami, Y. Impairment of plasmacytoid dendritic cells for IFN production by the ligand for immunoglobulin-like transcript 7 expressed on human cancer cells. Clin. Cancer Res. 2009, 15, 5733–5743. [Google Scholar] [CrossRef]
- Togashi, Y.; Shitara, K.; Nishikawa, H. Regulatory T cells in cancer immunosuppression—Implications for anticancer therapy. Nat. Rev. Clin. Oncol. 2019, 16, 356–371. [Google Scholar] [CrossRef]
- Moseman, E.A.; Liang, X.; Dawson, A.J.; Panoskaltsis-Mortari, A.; Krieg, A.M.; Liu, Y.J.; Blazar, B.R.; Chen, W. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J. Immunol. 2004, 173, 4433–4442. [Google Scholar] [CrossRef] [PubMed]
- Baban, B.; Chandler, P.R.; Sharma, M.D.; Pihkala, J.; Koni, P.A.; Munn, D.H.; Mellor, A.L. IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J. Immunol. 2009, 183, 2475–2483. [Google Scholar] [CrossRef] [PubMed]
- Sharma, M.D.; Hou, D.Y.; Liu, Y.; Koni, P.A.; Metz, R.; Chandler, P.; Mellor, A.L.; He, Y.; Munn, D.H. Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood 2009, 113, 6102–6111. [Google Scholar] [CrossRef]
- Zhang, H.; Gregorio, J.D.; Iwahori, T.; Zhang, X.; Choi, O.; Tolentino, L.L.; Prestwood, T.; Carmi, Y.; Engleman, E.G. A distinct subset of plasmacytoid dendritic cells induces activation and differentiation of B and T lymphocytes. Proc. Natl. Acad. Sci. USA 2017, 114, 1988–1993. [Google Scholar] [CrossRef] [PubMed]
- Ito, T.; Yang, M.; Wang, Y.H.; Lande, R.; Gregorio, J.; Perng, O.A.; Qin, X.F.; Liu, Y.J.; Gilliet, M. Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J. Exp. Med. 2007, 204, 105–115. [Google Scholar] [CrossRef] [PubMed]
- Conrad, C.; Gregorio, J.; Wang, Y.H.; Ito, T.; Meller, S.; Hanabuchi, S.; Anderson, S.; Atkinson, N.; Ramirez, P.T.; Liu, Y.J.; et al. Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cells. Cancer Res. 2012, 72, 5240–5249. [Google Scholar] [CrossRef] [PubMed]
- Ray, A.; Song, Y.; Chauhan, D.; Anderson, K.C. Blockade of ubiquitin receptor Rpn13 in plasmacytoid dendritic cells triggers anti-myeloma immunity. Blood Cancer J. 2019, 9, 64. [Google Scholar] [CrossRef]
- Buque, A.; Bloy, N.; Aranda, F.; Cremer, I.; Eggermont, A.; Fridman, W.H.; Fucikova, J.; Galon, J.; Spisek, R.; Tartour, E.; et al. Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. Oncoimmunology 2016, 5, e1149674. [Google Scholar] [CrossRef]
- Chaperot, L.; Blum, A.; Manches, O.; Lui, G.; Angel, J.; Molens, J.P.; Plumas, J. Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. J. Immunol. 2006, 176, 248–255. [Google Scholar] [CrossRef]
- Stary, G.; Bangert, C.; Tauber, M.; Strohal, R.; Kopp, T.; Stingl, G. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J. Exp. Med. 2007, 204, 1441–1451. [Google Scholar] [CrossRef]
- Parker, B.S.; Rautela, J.; Hertzog, P.J. Antitumour actions of interferons: Implications for cancer therapy. Nat. Rev. Cancer 2016, 16, 131–144. [Google Scholar] [CrossRef]
- Borden, E.C. Interferons alpha and beta in cancer: Therapeutic opportunities from new insights. Nat. Rev. Drug Discov. 2019, 18, 219–234. [Google Scholar] [CrossRef] [PubMed]
- Segura, E.; Durand, M.; Amigorena, S. Similar antigen cross-presentation capacity and phagocytic functions in all freshly isolated human lymphoid organ-resident dendritic cells. J. Exp. Med. 2013, 210, 1035–1047. [Google Scholar] [CrossRef] [PubMed]
- Meyer-Wentrup, F.; Benitez-Ribas, D.; Tacken, P.J.; Punt, C.J.; Figdor, C.G.; de Vries, I.J.; Adema, G.J. Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-alpha production. Blood 2008, 111, 4245–4253. [Google Scholar] [CrossRef]
- Tel, J.; Benitez-Ribas, D.; Hoosemans, S.; Cambi, A.; Adema, G.J.; Figdor, C.G.; Tacken, P.J.; de Vries, I.J. DEC-205 mediates antigen uptake and presentation by both resting and activated human plasmacytoid dendritic cells. Eur. J. Immunol. 2011, 41, 1014–1023. [Google Scholar] [CrossRef] [PubMed]
- Psarras, A.; Antanaviciute, A.; Alase, A.; Carr, I.; Wittmann, M.; Emery, P.; Tsokos, G.C.; Vital, E.M. TNF-alpha Regulates Human Plasmacytoid Dendritic Cells by Suppressing IFN-alpha Production and Enhancing T Cell Activation. J. Immunol. 2021, 206, 785–796. [Google Scholar] [CrossRef] [PubMed]
- Pahlavanneshan, S.; Sayadmanesh, A.; Ebrahimiyan, H.; Basiri, M. Toll-Like Receptor-Based Strategies for Cancer Immunotherapy. J. Immunol. Res. 2021, 2021, 9912188. [Google Scholar] [CrossRef] [PubMed]
- Molenkamp, B.G.; van Leeuwen, P.A.; Meijer, S.; Sluijter, B.J.; Wijnands, P.G.; Baars, A.; van den Eertwegh, A.J.; Scheper, R.J.; de Gruijl, T.D. Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients. Clin. Cancer Res. 2007, 13, 2961–2969. [Google Scholar] [CrossRef] [PubMed]
- Molenkamp, B.G.; Sluijter, B.J.; van Leeuwen, P.A.; Santegoets, S.J.; Meijer, S.; Wijnands, P.G.; Haanen, J.B.; van den Eertwegh, A.J.; Scheper, R.J.; de Gruijl, T.D. Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients. Clin. Cancer Res. 2008, 14, 4532–4542. [Google Scholar] [CrossRef]
- Sluijter, B.J.; van den Hout, M.F.; Koster, B.D.; van Leeuwen, P.A.; Schneiders, F.L.; van de Ven, R.; Molenkamp, B.G.; Vosslamber, S.; Verweij, C.L.; van den Tol, M.P.; et al. Arming the Melanoma Sentinel Lymph Node through Local Administration of CpG-B and GM-CSF: Recruitment and Activation of BDCA3/CD141(+) Dendritic Cells and Enhanced Cross-Presentation. Cancer Immunol. Res. 2015, 3, 495–505. [Google Scholar] [CrossRef] [Green Version]
- Kalb, M.L.; Glaser, A.; Stary, G.; Koszik, F.; Stingl, G. TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: Mechanisms of imiquimod- and IFN-alpha-mediated antitumor reactivity. J. Immunol. 2012, 188, 1583–1591. [Google Scholar] [CrossRef] [PubMed]
- Wu, J.; Li, S.; Yang, Y.; Zhu, S.; Zhang, M.; Qiao, Y.; Liu, Y.-J.; Chen, J. TLR-activated plasmacytoid dendritic cells inhibit breast cancer cell growth in vitro and in vivo. Oncotarget 2017, 8, 11708–11718. [Google Scholar] [CrossRef] [PubMed]
- Anandasabapathy, N.; Breton, G.; Hurley, A.; Caskey, M.; Trumpfheller, C.; Sarma, P.; Pring, J.; Pack, M.; Buckley, N.; Matei, I.; et al. Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers. Bone Marrow Transpl. 2015, 50, 924–930. [Google Scholar] [CrossRef]
- Bhardwaj, N.; Friedlander, P.A.; Pavlick, A.C.; Ernstoff, M.S.; Gastman, B.R.; Hanks, B.A.; Curti, B.D.; Albertini, M.R.; Luke, J.J.; Blazquez, A.B.; et al. Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets. Nat. Cancer 2020, 1, 1204–1217. [Google Scholar] [CrossRef]
- Filin, I.Y.; Kitaeva, K.V.; Rutland, C.S.; Rizvanov, A.A.; Solovyeva, V.V. Recent Advances in Experimental Dendritic Cell Vaccines for Cancer. Front. Oncol. 2021, 11, 730824. [Google Scholar] [CrossRef]
- Kantoff, P.W.; Higano, C.S.; Shore, N.D.; Berger, E.R.; Small, E.J.; Penson, D.F.; Redfern, C.H.; Ferrari, A.C.; Dreicer, R.; Sims, R.B.; et al. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. N. Engl. J. Med. 2010, 363, 411–422. [Google Scholar] [CrossRef]
- Laustsen, A.; Bak, R.O.; Krapp, C.; Kjær, L.; Egedahl, J.H.; Petersen, C.C.; Pillai, S.; Tang, H.Q.; Uldbjerg, N.; Porteus, M.; et al. Interferon priming is essential for human CD34+ cell-derived plasmacytoid dendritic cell maturation and function. Nat. Commun. 2018, 9, 3525. [Google Scholar] [CrossRef] [PubMed]
- Laustsen, A.; van der Sluis, R.M.; Gris-Oliver, A.; Hernández, S.S.; Cemalovic, E.; Tang, H.Q.; Pedersen, L.H.; Uldbjerg, N.; Jakobsen, M.R.; Bak, R.O. Ascorbic acid supports ex vivo generation of plasmacytoid dendritic cells from circulating hematopoietic stem cells. eLife 2021, 10, e65528. [Google Scholar] [CrossRef]
- Boon, T.; Coulie, P.G.; Van den Eynde, B.J.; van der Bruggen, P. Human T cell responses against melanoma. Annu. Rev. Immunol. 2006, 24, 175–208. [Google Scholar] [CrossRef]
- Aspord, C.; Charles, J.; Leccia, M.T.; Laurin, D.; Richard, M.J.; Chaperot, L.; Plumas, J. A novel cancer vaccine strategy based on HLA-A*0201 matched allogeneic plasmacytoid dendritic cells. PLoS ONE 2010, 5, e10458. [Google Scholar] [CrossRef] [Green Version]
- Aspord, C.; Leccia, M.T.; Salameire, D.; Laurin, D.; Chaperot, L.; Charles, J.; Plumas, J. HLA-A(*)0201(+) plasmacytoid dendritic cells provide a cell-based immunotherapy for melanoma patients. J. Invest. Dermatol. 2012, 132, 2395–2406. [Google Scholar] [CrossRef] [PubMed]
- Lenogue, K.; Walencik, A.; Laulagnier, K.; Molens, J.P.; Benlalam, H.; Dreno, B.; Coulie, P.; Pule, M.; Chaperot, L.; Plumas, J. Engineering a Human Plasmacytoid Dendritic Cell-Based Vaccine to Prime and Expand Multispecific Viral and Tumor Antigen-Specific T-Cells. Vaccines 2021, 9, 141. [Google Scholar] [CrossRef]
- Schreibelt, G.; Bol, K.F.; Westdorp, H.; Wimmers, F.; Aarntzen, E.H.; Duiveman-de Boer, T.; van de Rakt, M.W.; Scharenborg, N.M.; de Boer, A.J.; Pots, J.M.; et al. Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells. Clin. Cancer Res. 2016, 22, 2155–2166. [Google Scholar] [CrossRef]
- Westdorp, H.; Creemers, J.H.A.; van Oort, I.M.; Mehra, N.; Hins-de Bree, S.M.; Figdor, C.G.; Witjes, J.A.; Schreibelt, G.; de Vries, I.J.M.; Gerritsen, W.R.; et al. High Health-Related Quality of Life During Dendritic Cell Vaccination Therapy in Patients With Castration-Resistant Prostate Cancer. Front. Oncol. 2020, 10, 536700. [Google Scholar] [CrossRef]
Clinical Trial Identifier | Recruitment Status | Principal Investigator | Institution | Condition | Phase | Number of Participants | Therapeutic Product | Dose | Toxicity | Immune Response Observed | Clinical Outcome | References |
---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT01690377 | Completed | C J A Punt | Radboud University Medical Center | Metastatic melanoma | phase I | 15 | Natural circulating pDCs loaded with peptides derived from melanoma TAAs | 0.3–3 × 106 pDCs/injection | Grade 1 flu-like symptoms | Upregulation of CD80, CD83, CD86, MHC class I, and class II in activated pDCs Migration of activated pDCs in vivo Tumor-specific CD4+ and CD8+ T-cell responses | Median PFS: 4 months Median OS: 22 months | Tel, Aarntzen et al., 2013 [29] |
C G Figdor | ||||||||||||
NCT01863108 | Completed | J Plumas | Grenoble University Hospital | Metastatic stage IV melanoma | phase I | 9 | GeniusVac-Mel4: allogeneic PDC line loaded with four melanoma TAAs | 4–60 × 106 pDCs/injection | General disorders. Administration site events. Other adverse events (i.e., nausea, abdominal pain, and decreased appetite). Grade 3 adverse events (pain and lymphadenitis). | Antigen-specific T cells Recruitment of anti-vaccine T cells into the tumor bed | Stable disease for 16 to 48 weeks in 4 patients | Charles, Chaperot et al., 2020 [31] |
J Charles | ||||||||||||
NCT02692976 | Completed | W R Gerritsen | Radboud University Nijmegen Medical Centre | Prostatic Neoplasms | phase IIa | 21 | cDC2, pDCs or a combination of both loaded with three prostate TAAs |
| Grade 1–2 toxicity (flu-like symptoms, fatigue, upper respiratory infections, injection site reactions, etc.) | Antigen-specific T cells with no significant differences between treatments IFN-γ production | Median PFS for all patients: 9.5 months Median OS: not reached | Westdorp, Creemers et al., 2019 [30] |
F Witjes | ||||||||||||
J de Vries | ||||||||||||
NCT04212377 | Completed | J de Vries | Radboud University Medical Center | Metastatic Endometrial Cancer | phase II | 8 | cDC2 and pDCs loaded with TAAs | |||||
NCT03970746 | Recruiting | J Vansteenkiste | PDC*line Pharma | Non-small-cell lung cancer | phase I/II | Allogeneic PDC line loaded with TAAs |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Hernández, S.S.; Jakobsen, M.R.; Bak, R.O. Plasmacytoid Dendritic Cells as a Novel Cell-Based Cancer Immunotherapy. Int. J. Mol. Sci. 2022, 23, 11397. https://doi.org/10.3390/ijms231911397
Hernández SS, Jakobsen MR, Bak RO. Plasmacytoid Dendritic Cells as a Novel Cell-Based Cancer Immunotherapy. International Journal of Molecular Sciences. 2022; 23(19):11397. https://doi.org/10.3390/ijms231911397
Chicago/Turabian StyleHernández, Sabina Sánchez, Martin Roelsgaard Jakobsen, and Rasmus O. Bak. 2022. "Plasmacytoid Dendritic Cells as a Novel Cell-Based Cancer Immunotherapy" International Journal of Molecular Sciences 23, no. 19: 11397. https://doi.org/10.3390/ijms231911397
APA StyleHernández, S. S., Jakobsen, M. R., & Bak, R. O. (2022). Plasmacytoid Dendritic Cells as a Novel Cell-Based Cancer Immunotherapy. International Journal of Molecular Sciences, 23(19), 11397. https://doi.org/10.3390/ijms231911397